Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals. The case centers on the federal 340B program,

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis.

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.

Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to sell its psoriasis treatment Stelara and blood thinner Xarelto to some hospitals at full price before applying drug rebates.

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a drug-discount program.

The company filed a lawsuit asking for a federal court’s permission to change when it gives lucrative drug discounts to hospitals.

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive rebates later. Read more here.